Compare TNET & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNET | BEAM |
|---|---|---|
| Founded | 1988 | 2017 |
| Country | United States | United States |
| Employees | 2700 | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 3.0B |
| IPO Year | 2000 | 2019 |
| Metric | TNET | BEAM |
|---|---|---|
| Price | $59.58 | $27.75 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 12 |
| Target Price | ★ $65.80 | $50.75 |
| AVG Volume (30 Days) | 321.6K | ★ 2.7M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.57% | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ 1.90 | N/A |
| Revenue | ★ $5,010,000,000.00 | $24,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.30 | $33.77 |
| P/E Ratio | $31.89 | ★ N/A |
| Revenue Growth | N/A | ★ 33.33 |
| 52 Week Low | $33.67 | $15.60 |
| 52 Week High | $72.84 | $38.26 |
| Indicator | TNET | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 72.38 | 34.36 |
| Support Level | $57.98 | $26.96 |
| Resistance Level | $64.03 | $29.68 |
| Average True Range (ATR) | 1.97 | 2.45 |
| MACD | 0.50 | -0.95 |
| Stochastic Oscillator | 81.51 | 5.82 |
Trinet Group Inc provides human resources solutions for small and medium-sized businesses through technology-enabled services. Its offerings include human capital expertise, employee benefits such as health insurance and retirement plans, payroll and payroll tax administration, risk mitigation, and compliance consulting. The company provides its services through professional employer organization (PEO) services delivered via a co-employment model, as well as administrative services organization (ASO) offerings. The majority of the company's revenue is derived from the insurance-related billings and administrative fees collected from PEO clients.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.